Has Filippo Milano received payments from drug or device companies?

Yes. Drug and device makers reported $60,633 in general payments to Filippo Milano across 33 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Filippo Milano did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Filippo Milano come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Filippo Milano

Hematology & Oncology · Seattle, WANPI 1083842215

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $49,180 of the $60,633 with a category attached, or 81.1%. 9 manufacturers reported payments, led by Gamida Cell Inc. at 36.1% of the total. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,633in general payments, 2019–2025

Across 33 payments — averaging $1837.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gamida Cell Inc.$22K
Medexus Pharma, Inc.$18K
Chugai Pharmaceutical Co., Ltd.$14K
Takeda Pharmaceuticals U.S.A., Inc.$6K
National Marrow Donor Program$498
Jazz Pharmaceuticals Inc.$474
plus $314 from 3 others

$679,045in research payments, 2019–2025

Across 5 payments — averaging $135,809 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Jazz Pharmaceuticals Inc.$598K
Amgen$69K
Medexus Pharma, Inc.$12K

What the payments were for

Consulting fees$49,18081%
Travel & lodging$10,22917%
Food & beverage$1,2242%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gamida Cell Inc.(2 entities)	8	$21,886
Medexus Pharma, Inc.	9	$17,735
Chugai Pharmaceutical Co., Ltd.	4	$13,785
Takeda Pharmaceuticals U.S.A., Inc.	1	$5,940
National Marrow Donor Program	2	$498
Jazz Pharmaceuticals Inc.	5	$474
Seagen Inc.	1	$141
Legend Biotech USA Inc.	2	$106
Siemens Medical Solutions USA, Inc.	1	$66

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,633 in reported general payments places this provider in the 90th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington →

Other hematology & oncology in Seattle

John PesandoSeattle$15.7M
Jill JohnsenSeattle$991K
Fengting YanSeattle$841K
John PagelSeattle$725K
Lawrence FongSeattle$546K
Langdon MillerSeattle$457K
Mazyar ShadmanSeattle$226K
Catherine LeeSeattle$199K
Celestia HiganoSeattle$164K
Ryan CassadaySeattle$151K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →